SEARCH LISTED COMPANY
ANY AUS OR NZ COMPANY
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
| FROM | TO | |
|---|---|---|
| TRIVARX LTD | 16/10/2023 | |
| MEDIBIO LIMITED | 01/12/2014 | 16/10/2023 |
| BIOPROSPECT LIMITED | 01/12/2014 |
Level 1, 200 Mary Street Brisbane QLD 4000
Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)name changed to TrivarX Ltd | 16/10/2023 |
The suspension of trading in the securities of Medibio Limited will be lifted immediately following the release by MEB of an announcement regarding a capital raising. | 22/06/2022 |
Commitments received for $1.4 million placement at $0.0015 (0.15 cents) per fully paid ordinary share. Issue price of $0.0015 (0.15 cents). Placement to be completed over two tranches. Investors under the placement to be offered one (1) free attaching option for every one (1) new share subscribed for, exercisable at $0.004 (0.4 cents) on or before an expiry date of 15 June 2027. Issue of securities under Tranche 2 are subject to shareholder approval, to be sought at an EGM to be held in August 2022. | 22/06/2022 |
The Company now expects to make an announcement in relation to the capital raising before the commencement of trading on 21 June 2022 and confirms its request that the suspension will continue until the announcement is made. | 20/06/2022 |
The securities of Medibio Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of MEB, pending the release of an announcement regarding a capital raising. | 16/06/2022 |
The suspension of trading in the securities of Medibio Limited will be lifted immediately following the release by MEB of an announcement regarding its capital raising. | 10/07/2019 |
Commitments were received for $3.5 million placement at $0.01 per fully paid ordinary share. SPP were on the same terms, underwritten for $520,000. Issue price of $0.01, a 51.6% discount to the 5-day VWAP. Placement to be completed over two stages. ✓ Investors under the placement and Eligible shareholders under the SPP to be offered 1 free attaching option for each new share subscribed for, exercisable at $0.03 until an expiry date of 1 December 2021 and for which the Company will seek quotation on the ASX. Existing holders of convertible notes have agreed to early conversion of their notes for fully paid ordinary shares at a conversion price equal to the issue price under the Placement. Each noteholder will be offered 1 free New Option for each Share issued. Issue of securities under Stage 2 of the Placement, the SPP (including underwritten shortfall) and the early conversion of notes is subject to shareholder approval, to be sought at an EGM to be held in late August 2019. | 10/07/2019 |
The securities of Medibio Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of MEB, pending the release of an announcement regarding a capital raising. | 09/07/2019 |
we understand that on or about this date the company consolidated its shares 1 for 100 | 20/03/2015 |
The suspension of trading in the securities of Medibio Limited (the "Company") will be lifted immediately following receipt of an announcement in relation to an agreement with John Hopkins Hospital. Security Code: MEB | 01/12/2014 |
name changed from Bioprospect Limited - was previously called MEDIA ASIA PACIFIC LIMITED which delisted from ASX on 31 August 1998 following the company's failure to lodge annual listing fees in respect of the year ended 30/06/99. | 01/12/2014 |
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 09/11/2018 | Chris Indermaur | 200,000 | $0.040 | $8,000.00 |
| 06/11/2018 | Andrew Maxwell | 216,002 | $0.044 | $9,434.00 |
| 02/08/2017 | Andrew Maxwell | 26,000 | $0.380 | $9,880.00 |
| 10/07/2017 | Peter Carlisle | 5,500 | $0.373 | $2,053.00 |
| 18/04/2017 | Jack Cosentino | 100,000 | $0.370 | $37,000.00 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| David Trimboli | Non Exec Chairman | 25/08/2022 |
| Steve Sathre | CFO | 01/01/2019 |
| Chris Ntoumenopoulos | Non Exec Director | 15/02/2023 |
| Liwanag Ojala | Non Exec Director | 29/08/2019 |
| Lisa Heine | Non Exec Director | 29/08/2019 |
| Thomas R. Young | Non Exec Director | 19/09/2022 |
| Lisa Ide | Non Exec Director | 29/08/2019 |
| Stephen Buckley | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|
Date of first appointment, title may have changed.
